Imaging Approaches in Prostate Cancer
Daniel P. Petrylak, MD, director, Prostate and GU Medical Oncology, Yale Cancer Center, describes imaging approaches in prostate cancer.
Clinical Pearls I
Daniel P. Petrylak, MD, director, Prostate and GU Medical Oncology, Yale Cancer Center, describes imaging approaches in prostate cancer.
- Sodium fluoride PET represents a sensitive way of detecting bone metastases
- Sodium fluoride PET is reasonable to use before treatment with enzalutamide, sipuleucel-T, or abiraterone, in patients with rising PSA and negative conventional imaging
Clinical Pearls II
- The Artemis device is being looked at in clinical studies to help detect prostate cancer in localized biopsies
- Sodium acetate PET and amino acid imaging are still under investigation
- Petrylak is interested in research into imaging for targeted therapies to check for activity and eligibility
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
FPI-2265 Dosing Commences in Phase 2 AlphaBreak Trial for mCRPC
May 10th 2024The first patient has been dosed in the phase 2 AlphaBreak trial with FPI-2265 for the treatment of metastatic castration-resistant prostate cancer, marking a significant milestone in advanced cancer treatment.
Read More
